Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 1/20 | 0.55 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.55 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.55 |
| ▸ | TPX2 | Q9ULW0 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | PIM1 | P11309 | 2/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.40 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.40 |
| ▸ | JAK1 | P23458 | 4/20 | 0.39 |
| ▸ | JAK2 | O60674 | 3/20 | 0.39 |
| ▸ | DRD1 | P21728 | 1/20 | 0.38 |
| ▸ | AKT1 | P31749 | 1/20 | 0.38 |
| ▸ | AKT2 | P31751 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | BRD2 | P25440 | 1/20 | 0.37 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.37 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.37 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18437175 | 0.76 | PDE3B (0.58) | MAPK1TRPA1JAK2DRD1CLK2 | |
| SCHEMBL5806168 | 0.76 | PDE3B (0.58) | AURKBTRPA1JAK2MAPTCLK2 | |
| SCHEMBL30557174 | 0.74 | AURKA (0.48) | AURKAAURKBINCENPTPX2MAPK1 | |
| SCHEMBL171455 | 0.74 | JAK2 (0.61) | AURKAAURKBINCENPTPX2MAPK1 | |
| SCHEMBL29541277 | 0.74 | JAK2 (0.61) | AURKAAURKBINCENPTPX2MAPK1 | |
| SCHEMBL30557210 | 0.72 | PIK3CD (0.58) | AURKAAURKBINCENPTPX2PIM1 | |
| SCHEMBL2239177 | 0.71 | AURKB (1.00) | AURKAAURKBINCENPTPX2JAK1 | |
| SCHEMBL31061291 | 0.71 | AURKB (1.00) | AURKAAURKBINCENPTPX2JAK1 | |
| SCHEMBL29893852 | 0.70 | KDM4E (0.45) | TRPA1DRD1PDE3BPDE3A | |
| SCHEMBL30557126 | 0.69 | BRD4 (0.55) | AURKAAURKBINCENPTPX2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230226064-A1 | ORAL LIQUID FORMULATIONS OF RUXOLITINIB | NOVARTIS PHARMACEUTICALS CORPORATION | 2023-07-20 | — | — | US | disclosed |
| US-20230226064-A1 | ORAL LIQUID FORMULATIONS OF RUXOLITINIB | NOVARTIS PHARMACEUTICALS CORPORATION | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230226064-A1 | ORAL LIQUID FORMULATIONS OF RUXOLITINIB | JAK1, JAK2, JAK3 | AURKA 402/4885AURKB 478/4885INCENP 4175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.